In a shining moment for Uganda and the African scientific community, Dr Matthias Magoola, founder of Dei Biopharma, has been awarded one of the highest international honors in the pharmaceutical world—the Pharma Ratna Universe Award 2025, presented in Ahmedabad, Gujarat, India.
The award ceremony, held on April 20 at the Taj Skyline hotel, recognized global leaders in pharmaceutical innovation. Ms. Olivia Kemigisa, head of Human Capital at Dei Biopharma Ltd, received the award on Dr Magoola’s behalf. In their citation, the Pharma Ratna Awards Committee described Dr Magoola as, “A man who made the whole of Africa proud with his visionary approach.
He started his career from zero, and now he is a billionaire.” The citation continued: “His vision is to make Africa free from malaria and other dreaded diseases. He owns Africa’s largest pharmaceutical and biotech company.”
But for Dr Magoola, this honor is not just a personal achievement—it represents the rise of African-led innovation on a global scale.
A SYMBOL OF RESILIENCE AND INNOVATION
Reacting to the award, Hitesh Upreti, CEO of Dei Biopharma, said the accolade reflects the global recognition of Dr Magoola’s mission.
“This award is a salute to the spirit of innovation, resilience and purpose that Dr Magoola embodies,” Upreti stated.
“We are grateful to Pharma Ratna Universe 2025 for recognising African excellence on this global stage. We are even more committed now—to rise higher, reach farther, and serve better.”
Founded and incorporated in Uganda, Dei Biopharma Ltd specializes in cutting-edge research and the manufacture of essential medicines and vaccines. The company is currently developing a multi-billion-dollar pharmaceutical manufacturing facility in Matugga, just outside Kampala.
A VISION BACKED BY THE STATE
Dr Magoola’s groundbreaking work has not gone unnoticed at home. In a recent meeting held on April 13 at State House, Entebbe, President Yoweri Museveni pledged continued government support for Dei Biopharma’s projects.
The president committed to fast-tracking the National Drug and Health Products Act, a crucial step toward helping Uganda’s National Drug Authority (NDA) attain World Health Organization Maturity Level 3 Accreditation—a key benchmark that will enable locally produced vaccines to be licensed for global use.
“We are grateful for the support from the government, and especially His Excellency President Yoweri Museveni,” said Dr Magoola.
“Without his dedicated support, we wouldn’t be achieving these milestones. These achievements are not just mine—they are for Uganda and specifically for our dear president, who has always stood up for scientists in this country.”
DEI BIOPHARMA’S IMPACT EXTENDS WELL BEYOND BORDERS
On February 6, 2025, the United States Patent and Trademark Office (USPTO) published Dr. Magoola’s latest patent—a revolutionary cancer treatment using guided RNA technology.
This breakthrough therapy employs a novel composition of guided RNA attached to the Cas9 protein, which targets and disables mutated genes responsible for cancer.
“Instead of allowing the cell to repair the disrupted gene, the method prevents this repair, leading to the destruction of cancerous cells,” Dr. Magoola explained.
This technique builds on the foundational CRISPR-Cas9 technology, for which Professors Emmanuelle Charpentier and Jennifer Doudna won the 2020 Nobel Prize in Chemistry.
But Dr Magoola’s innovation takes the gene-editing tool one critical step further—targeting only cancer cells while sparing healthy ones, and eliminating the harsh side effects of conventional cancer therapies.
Earlier this year, on January 7, the USPTO also accepted a world-first patent for a universal vaccine against foot and mouth disease (FMD) developed by Dei Biopharma. Titled “Affordable Universal Fusion Vaccine for Foot and Mouth Disease Infections,” the vaccine is expected to save Uganda billions of shillings by reducing the reliance on imported animal vaccines.
A CATALYST FOR AFRICAN TRANSFORMATION
Dr Magoola has filed over 100 patents with the USPTO for treatments and vaccines targeting cancer, HIV, Alzheimer’s, sickle cell disease, malaria, tuberculosis, and diabetes.
He is among a new generation of African scientists changing the narrative—from aid dependency to homegrown solutions for Africa’s greatest health challenges.